There is a need for better treatment for cough. Unexplained or chronic refractory cough (CRC) is the focus of several recent and ongoing large drug trials, with particular interest in antagonists of ATP-stimulated P2X receptors (1). Although such drugs appear very promising, there are nonresponders, and side effects may be unacceptable to some (2). Hence, a requirement for alternative approaches, not only for CRC but also for cough associated with chronic and incurable diseases of the lung, such as lung cancer, is needed. In this issue of the Journal, Smith and colleagues (pp. 737–745) present their findings on aprepitant for cough in non–radically treatable lung cancer, which, considering the current need, are very welcome (3).